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Successful kidney transplantation was recently shown to lead
to improvement in the cognitive performance of patients on
chronic dialysis. To examine whether the early cognitive
benefits of transplantation continue to develop over time,
along with the patients’ ongoing recovery, we addressed
these questions in a prospective controlled study of 27
dialyzed patients who subsequently received a kidney
transplant, 18 dialyzed patients awaiting kidney transplant,
and 30 matched controls without kidney disease. Overall,
successful kidney transplant contributed to a statistically
significant improvement in performance on tests of motor/
psychomotor speed, visual planning, memory, and abstract
reasoning tested 1 year later. We also studied whether the
cognitive performance of patients maintained on dialysis is
stable or declines over time and found that it actually
declined over this time even in adequately dialyzed patients.
Measures of memory functions were particularly affected.
This study indicates that the early beneficial effects of
transplantation are not transient and were still evident 1 year
following transplantation.
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There has been a growing number of studies indicating that
patients with chronic kidney disease (CKD), predominantly
older subjects with end-stage renal disease (ESRD), frequently
suffer from cognitive problems and, thus, perform poorly on
neuropsychological tests.1–10 It has been also demonstrated that
the severity of these deficits is often associated with the
glomerular filtration rate,11–13 and may thus represent a
consequence of impaired brain function because of the
accumulation of uremic toxins. This hypothesis has been
mostly supported by early studies showing that adequate
dialysis may reduce some of the cognitive dysfunction.14–18
Nonetheless, the etiology of cognitive impairment in CKD is
multifactorial,19–20 and some of the intellectual deficits may also
result from the CKD-related comorbidities (for example,
diabetes, hypertension, and coronary artery disease) and their
treatment (for example, coronary artery bypass grafting).21–26
Additionally, the hemodialysis itself, mostly by inducing cerebral
ischemia or cerebral edema, may produce new, or amplify pre-
existing, cognitive impairment,19,27–31 further compromising
patients’ quality of life, increase their mortality, resource
utilization, dementia risk, and costs of medical care.11,29,31–34
Unlike chronic dialysis and other symptomatic treatments,
kidney transplant has been considered the most effective
method for improvement of neuropsychological functions in
individuals with ESRD.3,18–20,35–39 Nonetheless, the majority
of studies demonstrating a positive impact of graft surgery on
cognitive abilities have several limitations (for example,
cross-sectional comparisons,35 small sample sizes,18,38,39
insufficient control of demographics and comorbidities,36,39
lack of a comprehensive assessment of all cognition,18,38
absence of well-matched controls,36,39 relatively short follow-
up,36,37and so on) that complicate the interpretation of
otherwise promising results. In particular, information
regarding the general or late post-transplant neuropsycholo-
gical outcomes is still very limited. For example, it remains
unknown whether the early beneficial cognitive effects of
kidney transplantation reported in our previous study37
continue to develop over time, along with patients’
continuous medical and functional recovery. This issue
appears to be of particular importance, as cognitive
limitations may significantly affect the adherence to
complex post-transplant medication regimens as well as the
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employment status following the organ surgery.40 Alternatively,
complications such as infections and/or immunosuppressive
therapy might markedly reduce the early positive effects of an
otherwise successful graft surgery. As a point of comparison, it
would be also interesting to determine whether cognition of
patients receiving chronic dialysis remains stable or declines
over time, as suggested by other research.27
Therefore, by overcoming most of the limitations of
previous studies, this single-center study aimed to better
address the question of cognitive outcomes following
successful kidney transplantation as well as the stability of
neuropsychological performance of adequately dialyzed
individuals with ESRD.
RESULTS
A total of 27 dialyzed patients with ESRD who subsequently
received kidney graft (TX), 18 dialyzed subjects who were
awaiting kidney transplant but, because of a lack of an
appropriate donor, had yet to receive it (NTX), as well as 30
demographically and clinically matched controls without
CKD were the participants for this study.
Demographic, clinical, and biochemical factors
There were no statistically significant group differences in
time between each testing session, demographics, CKD
comorbidities, premorbid intelligence, general cognition,
anxiety, and depression at baseline, although diabetes and
hypertension tended to be more prevalent among patients
with kidney transplant, as shown in Table 1.
For dialyzed subjects, no group differences in factors
specific for kidney population (for example, primary kidney
disease diagnosis, duration of CKD, time spent on dialysis,
type of dialysis, blood urea nitrogen, creatinine, hemoglobin,
albumin, and dialysis adequacy) emerged (Table 2).
Prospective neuropsychological assessment
Overall cognitive status. This part of the analysis aimed to
identify longitudinal changes in general cognition, as
measured by the MMSE (Mini-Mental State Examination).41
However, no statistically significant effects were identified.
Specific neuropsychological measures
Next, the performance of all three groups on specific
cognitive tests was analyzed prospectively over the time of
the study (baseline vs first follow-up vs second follow-up).
The analysis revealed statistically significant interactions
(P-values p0.001), as shown by the nonparallel lines in
Figure 1 (Supplementary Appendix online). That is, at
baseline, patients with kidney graft performed worse than
matched controls on all cognitive measures presented in
Table 1 | Demographic and clinical group characteristics
Group variable TX (n=27) NTX (n=18) MC (n=30) P-value
Mean age±s.d. 46.1±10.9 44.9±11.8 47.23±10.2 0.77
Mean years of education±s.d. 12.5±2.5 12.2±3.1 11.8±2.1 0.59
Sex (male), n (%) 19 (70.4) 10 (55.6) 22 (73.3) 0.42
Mean baseline MMSE±s.d. 28.44 (1.08) 28.39 (0.92) 29.00 (0.87) 0.06
Mean baseline Vocabulary±s.d. (WAIS-R-PL) 39.26 (8.13) 43.94 (8.91) 43.70 (6.70) 0.07
Mean time between baseline and first follow-up assessment (days)±s.d. 248.2±36.8 258.7±6.3 260.8±7.4 0.10
Mean time between first and second follow-up assessment (days)±s.d. 365.4±12.7 359.1±12.9 366.7±11.1 0.11
Mean time between baseline and second follow-up assessment (days)±s.d. 613.6±35.8 617.8±15.2 627.5±14.3 0.10
Mean baseline depression±s.d. (HAD) 4.59 (4.18) 4.39 (3.01) 3.80 (2.43) 0.64
Mean baseline anxiety±s.d. (HAD) 6.85 (4.26) 7.11 (2.87) 6.00 (3.23) 0.51
Hypertension, n (%)
Baseline 17 (63.0) 10 (55.6) 13 (43.3) 0.32
First follow-up 20 (74.1) 10 (55.6) 13 (43.3) 0.06
Second follow-up 21 (77.8) 10 (55.6) 14 (46.7) 0.05
Diabetes mellitus, n (%)
Baseline 6 (22.2) 2 (11.1) 5 (16.7) 0.62
First follow-up 8 (29.6) 2 (11.1) 5 (16.7) 0.26
Second follow-up 8 (29.6) 3 (16.7) 5 (16.7) 0.42
Hepatitis C, n (%)a 3 (11.1) 3 (16.7) 2 (6.7) 0.55
Coronary artery disease, n (%) at baseline
Baseline 7 (25.9) 4 (22.2) 3 (10.0) 0.28
First follow-up 7 (25.9) 4 (22.2) 3 (10.0) 0.28
Second follow-up 7 (25.9) 5 (27.8) 3 (10.0) 0.21
Coronary artery bypass grafting, n (%)a 2 (7.4) 1 (5.6) 1 (3.3) 0.79
Valvular heart diseasea,b,c 1 (3.7) 0 (0) 0 (0) —
Myocardial infarctiona,b 1 (3.7) 0 (0) 0 (0) —
Abbreviations: HAD, Hospital Anxiety and Depression Scale; MC, matched controls; MMSE, Mini-Mental State Examination; NTX, patients without kidney transplant; TX,
patients with kidney transplant; WAIS-R-PL, Wechsler Adult Intelligence Scale-Revised.
aNumber of patients with this condition did not change over the time of the study.
bCoronary angiography before transplantation unchanged, without coronary artery narrowings.
cSuccessfully treated with mitral valve replacement before transplantation.
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Figure 1 except the Finger Tapping Test (P-values ranging
from o0.001 to 0.04), whereas these differences were no
longer observed following transplantation. Furthermore,
despite initially similar scores on each of these tasks, during
follow-up patients with kidney graft tended to outperform
subjects remaining on dialysis (P-values ranging from
o0.001 to 0.05). On the Similarities test, however, patients
without kidney transplant scored significantly lower than
controls only at follow-up (P¼ 0.002). In addition to these
interactions, statistically significant main group effects
(or trends toward such effects) emerged for all tasks shown
in Figure 1 except the Similarities test (P-values ranging from
o0.001 to 0.009), indicating that patients who did not
receive kidney graft performed on these measures worse than
matched controls, regardless of the time of the assessment.
The analyses of the change in the performance revealed
that in subjects with kidney graft, a statistically significant
improvement on tasks assessing psychomotor speed, motor
abilities, abstract reasoning, and memory emerged over time,
as shown in Table 3. Importantly, however, the improved
performance on measures of psychomotor speed (up to
20.60%), motor abilities (up to 9.29%), and abstract
reasoning (12.44%) was already seen shortly after transplan-
tation (P-values ranging from o0.001 to 0.002), whereas a
significant increase in memory scores (up to 27.4%; P-values
ranging fromo0.001 to 0.005) typically emerged only 1 year
following surgery. For patients remaining on dialysis,
however, a significant decline in verbal learning of an average
of 6.9% (Po0.001) was observed (see Table 3). It is note-
worthy that the cognitive performance of matched controls
did not change significantly over the time of the study.
Dialysis modality and cognitive performance. To test if
dialysis modality might have modified the effects described
above, cognitive performance of both groups with CKD was
longitudinally compared with type of dialysis as a covariant.
Nonetheless, dialysis modality turned to have no impact on
our results.
Depression and anxiety. Last, we assessed potential
changes in depression and anxiety, as measured by the
Hospital Anxiety and Depression Scale,42 but no significant
effects or interactions emerged.
DISCUSSION
This longitudinal study assessed the effects of kidney
transplantation on cognition in dialyzed patients. Overall,
the results confirmed our recently published data indicating
that a successful kidney transplantation leads to a marked
improvement of performance on tests of psychomotor speed,
visual planning, retrieval of learned material, as well as
abstract reasoning, whereas scores on other neuropsycholo-
gical measures remain relatively stable over time. Thus, our
findings do not support the notion that memory may be the
only cognitive function that improves after transplantation.36
Moreover, by including an additional follow-up point, this
study overcame the main limitation of our previous research
and demonstrated that the early beneficial effects of graft
surgery are not transient, but are still present at 1 year
following transplantation. Additionally, in patients who
remained on dialysis, a statistically significant decline was
seen on the free recall measure of verbal memory. This
Table 2 | Comparison of factors specific for dialyzed patients
Group variable
TX
(n=27)
NTX
(n=18) P-value
GFR (ml/min per 1.73 m2)
Baseline o15 o15 —
First follow-up 51.6±16.9 o15 —
Second follow-up 57.2±17.6 o15 —
Primary kidney disease diagnosis, n (%) 0.98
Hypertensive nephropathy 7 (25.9) 5 (27.8)
Diabetes 4 (14.8) 2 (11.1)
Glomerulonephritis 9 (33.3) 6 (33.3)
Other 7 (25.9) 5 (27.8)
Mean duration of kidney disease
(years)±s.d.
10.9±8.5 13.2±10.7 0.44
Type of dialysis at baseline, n (%) 0.78
Hemodialysis 17 (63.0) 12 (66.7)
Peritoneal dialysis 10 (37.0) 6 (33.3)
Mean time on dialysis
(months)±s.d.
42.7±42.9 54.1±45.4 0.43
Mean Kt/V±s.d.
Hemodialysis only (per session)
Baseline 1.72±0.1 1.67±0.1 0.25
First follow-up — 1.64±0.0 —
Second-follow-up — 1.69±0.1 —
Peritoneal dialysis only (total weekly urea)
Baseline 2.34±0.4 2.25±0.1 0.61
First follow-up — 2.23±0.1 —
Second follow-up — 2.30±0.3 —
Mean blood urea nitrogen (mg/dl)±s.d.
Baseline 50.5±17.9 42.8±18.2 0.27
First follow-up 35.7±18.5 45.9±16.6 0.07
Second follow-up 29.3±11.6 44.8±15.9 o0.001
Mean creatinine (mg/dl)±s.d.
Baseline 8.4±2.9 8.8±2.9 0.71
First follow-up 1.83±0.4 8.9±2.5 o0.001
Second follow-up 1.65±0.3 8.7±2.3 o0.001
Mean albumin (g/dl)±s.d.
Baseline 3.9±0.28 4.0±0.27 0.67
First follow-up 4.1±0.17 4.0±0.23 0.18
Second follow-up 4.1±0.20 3.9±0.26 0.09
Mean hemoglobin (g/dl)±s.d.
Baseline 11.9±1.3 11.3±1.2 0.11
First follow-up 11.6±1.2 11.4±1.2 0.55
Second follow-up 12.0±1.2 11.4±1.3 0.23
rHuEPO treatment, n (%)
Baseline 23 (85.2) 17 (94.4) 0.33
First follow-up 13 (48.1) 17 (94.4) 0.001
Second follow-up 0 (0) 17 (94.4) —
Abbreviations: GFR, glomerular filtration rate; Kt/V, kinetic transfer/volume,
calculated for patients on hemodialysis (single-pool Daugirdas formula; performed
three times a week), and subjects on peritoneal dialysis separately; NTX, patients
without kidney transplant; rHuEPO, recombinant human erythropoietin; TX, patients
with kidney transplant.
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suggests that the cognitive performance of adequately
dialyzed patients may, nonetheless, decline slowly in specific
domains over a time period of B2 years, as posited by
Altmann et al.27 Moreover, the pattern of this deterioration,
characterized by progressive decline in free recall with no
change in recognition memory performance, appears con-
sistent with the subcortical pattern typically seen in dialyzed
patients with cerebrovascular changes.19,43–45
Although the improvement in cognitive performance
following kidney transplantation has been previously re-
ported,18,35–39 the interpretation of these findings remains
fairly limited, mostly because of a number of methodological
problems (for example, cross-sectional comparisons and
lacked well-matched control). For the same reasons, as most
of the former studies provided inconsistent evidence regard-
ing which cognitive domain improves most after graft
surgery,3,20 the question of which neuropsychological func-
tion is preferentially affected by CKD-related neurotoxicity
remained open. To our knowledge, this is the first prospective
study that clearly demonstrates the beneficial and relatively
long-lasting cognitive effects of a successful kidney trans-
plantation that cannot be attributed to a change in mood,
pretransplant dialysis modality, level of hemoglobin, or
learning effects of repeated administration of cognitive tasks.
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Figure 1 | Statistically significant main group effects as well as interactions between time and group for the longitudinal
neuropsychological assessment. Non-parallel lines in each panel represent interactions, whereas relatively parallel lines represent main
group effects. (a) Interaction: F¼ 10.48; Po0.001; Zp2¼ 0.23, main group effect: F¼ 6.56; P¼ 0.002; Zp2¼ 0.15. (b) Interaction: F¼ 8.23; Po0.001;
Zp2¼ 0.19, trend toward a main group effect: F¼ 5.23; P¼ 0.008; Zp2¼ 0.13. (c) Interaction: F¼ 5.17; P¼ 0.001; Zp2¼ 0.13, main group effect:
F¼ 6.61; P¼ 0.002; Zp2¼ 0.16. (d) Interaction: F¼ 6.26; Po0.001; Zp2¼ 0.15, trend toward a main group effect: F¼ 5.01; P¼ 0.009; Zp2¼ 0.12.
(e) Interaction: F¼ 6.63; Po0.001; Zp2¼ 0.16, main group effect: F¼ 16.28; Po0.001; Zp2¼ 0.31. (f) Interaction: F¼ 5.07; P¼ 0.001; Zp2¼ 0.12,
trend toward a main group effect: F¼ 5.25; P¼ 0.007; Zp2¼ 0.13. (g) Interaction: F¼ 9.57; Po0.001; Zp2¼ 0.23, main group effect: F¼ 10.81;
Po0.001; Zp2¼ 0.21. (h) Interaction: F¼ 6.61; Po0.001; Zp2¼ 0.16. (i) Interaction: F¼ 9.54; Po0.001; Zp2¼ 0.21, main group effect: F¼ 12.87;
Po0.001; Zp2¼ 0.26. BVMT-R, Brief Visual Memory Test-Revised; MC, matched controls; NTX, patients without kidney transplant; RAVLT, Rey
Auditory Verbal Learning Test; RCF, Rey-Osterrieth Complex Figure; TMT, Trail Making Test; TX, patients with kidney transplant. #The higher
the scores, the slower, more impaired the performance. wTrend towards statistical significance.
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Also, the fact that the cognitive recovery was predominantly
seen on tests relying on psychomotor speed is consistent with
the observation of post-transplant improvement in P300
latency, a motor-free event-related potential that appears to
be a sensitive electroencephalogram index of mental proces-
sing speed.38 Moreover, as the cognitive improvement in
psychomotor speed, visual planning, and abstract thinking
emerged shortly after transplantation, it is likely that these
preoperative cognitive changes were specifically related to
the accumulation of toxins in the brain. This hypothesis is
further supported by findings indicating improvements in
psychomotor speed in patients converted from thrice-weekly
hemodialysis to daily dialysis.46
In contrast, as a significant recovery of memory function
was generally not observed until 1 year following transplan-
tation, it seems probable that memory problems in dialyzed
patients are only indirectly linked to the effects of CKD-
related neurotoxicity. For example, knowing that cerebrovas-
cular changes contribute to defective learning and free recall
of newly learned information,47,48 memory deficits in this
population might be partly associated with factors such as
cerebrovascular disease, being a frequent adverse effect of
chronic dialysis. Thus, the postsurgery improvement in
memory could require more time needed for patients’
general functional and medical recovery, including the
enhancement in vascular factors.43,44 Alternatively, the failure
of kidney transplant to reverse memory problems shortly
after surgery could have been because of the early side effects
of high doses of immunosuppressive therapy.49 Furthermore,
it is possible that, in comparison with other neuropsycho-
logical measures used in this study, memory tests might have
been less sensitive and stringent to detect a change in
cognitive performance shortly after kidney surgery. Also,
improved memory scores could have resulted from the
overall gain in mental efficiency and executive functioning.
Although this study was not designed to identify clinically
relevant cognitive impairment, the general cognitive status of
all our participants was normal, with no change in the
MMSE score over time. Thus, this finding is consistent with
the results of other investigators,27,39,45 positing that the
MMSE alone, relying heavily on language, may not be
sensitive enough to detect rather subtle and quite specific
non-language cognitive deficits associated with CKD and its
treatment. For this reason, scores on MMSE may not be
helpful in predicting cognitive outcomes, activities of daily
living, and adherence to complex medication regimens
following transplantation.
Nonetheless, although our findings of improved cognitive
performance after kidney transplantation seem to be robust,
this study has several limitations. For example, the un-
predictable organ availability made the time between baseline
and the first follow-up among our graft recipients variable
Table 3 | Differences between groups in percentage change from baseline to second follow-up
Mean percentage change from baseline to second follow-upa
Function assessed Test TX NTX MC P-valueb
General cognitive status MMSE 1.95 0.44 0.28 0.15
Verbal memory RAVLT (total learning) 11.07 6.92 0.12 o0.001c,d
RAVLT (delayed recall) 25.02 2.39 4.35 o0.001c
RAVLT (recognition) 1.35 0.09 0.05 0.82
Visual memory BVMT-R (total recall) 16.98 0.22 0.28 0.003e
BVMT-R (delayed recall) 18.82 4.02 2.56 0.005e
BVMT-R (recognition) 2.22 2.59 0.44 0.52
RCF (delayed recall) 27.40 5.65 1.76 o0.001c
Constructional praxis RCF (copy) 0.23 0.99 0.72 0.34
Attention Digit Span (forward) 4.97 0.05 5.48 0.58
Working memory Digit Span (backward) 0.05 4.03 1.48 0.85
Motor abilities Tapping (dominant hand) 6.81 4.89 1.73 0.001f
Tapping (non-dominant hand) 9.21 2.96 2.10 o0.001c
Psychomotor speed/ executive functions TMT-A 22.49 1.97 3.48 o0.001c
TMT-B 15.40 9.13 2.86 0.001f
Digit Symbol 19.45 5.07 1.18 o0.001c
Abstract reasoning Similarities 13.65 5.06 1.05 o0.001c
Verbal fluency Verbal fluency (letter) 0.89 1.08 0.56 0.92
Verbal fluency (category) 4.72 1.29 3.19 0.36
Semantic knowledge Vocabulary 1.64 0.07 0.62 0.40
Abbreviations: BVMT-R, Brief Visual Memory Test-Revised; MC, matched controls; MMSE, Mini-Mental State Examination; NTX, patients without kidney transplant; RAVLT, Rey
Auditory Verbal Learning Test; RCF, Rey-Osterrieth Complex Figure; TMT, Trail Making Test; TX, patients with kidney transplant.
aMean percentage change that is positive indicates an improvement and the numbers that are negative indicate a decline.
bSignificance level of one-way analysis of variance (ANOVA), corrected for multiple comparisons, was set at Pp0.002.
Superscripts indicate which between-group differences in change in the performance between testing points were significant, assessed using post hoc comparisons with
Tukey’s test.
cStatistically significant difference in change between the TX group and the two other groups.
dStatistically significant difference in change between the NTX and the MC groups.
eTrend toward statistical significance.
fStatistically significant difference in change between the TX and the NTX groups.
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and rather long. Thus, the change in cognitive function
observed in this group might be difficult to interpret merely
as a result of transplantation and not as an additive effect of
the time before surgery and the post-transplantation time.
Nonetheless, as the individuals who received kidney graft had
no other medical intervention between baseline and their first
follow-up, and a subtle decline was seen in subjects
remaining on dialysis, it is unlikely that any other factor
but transplantation could have contributed to the improved
cognition in this group. Because of small sample sizes as well
as a relatively young age of patients with CKD, however, our
results may not be easily generalized. Also, a small number of
kidney graft recipients made us unable to determine the
impact of specific immunosuppressive drug or protocol on
cognitive function and to assess a potentially differential
effect of the type of graft on post-transplant cognition.
Furthermore, small sample sizes might have also limited the
power to detect more pronounced intellectual deterioration
in dialyzed subjects. Moreover, both the rate of cognitive
improvement following transplantation and the rate of
cognitive decline in patients maintaining on dialysis might
have been modified by CKD comorbidities, particularly the
risk factors for cerebrovascular disease. Therefore, prospec-
tive multicenter studies with larger cohorts are required to
better understand the complexity of cognitive recovery after
kidney transplantation and to determine the potential
modifiers of such recovery.
MATERIALS AND METHODS
Participants
All individuals were right-handed, native Polish speakers who
completed a neuropsychological testing on the following long-
itudinal schedule: baseline, 8, and 20 months.
Patients with ESRD. All 45 eligible subjects with ESRD,
recruited from the Department of Nephrology, Transplantology
and Internal Medicine, Medical University of Gdan´sk from January
2005 to July 2008, were from a regional waitlist of 59 dialyzed
patients awaiting kidney transplant.
Participants were enrolled if they were between 21 and 65 years
of age, had no malignancies, stroke, transient ischemic attack, or any
other clinically evident signs of cerebrovascular disease as reflected
by neurological deficits. Also, individuals were not eligible if they
had uncontrolled hypertension, diabetes and/or anemia, mental
retardation, psychiatric disorders, psychoactive drug treatment,
dementia, or alcohol abuse. Additionally, subjects who had clinically
relevant visual or hearing difficulties as well as other major organ
failure (for example, end-stage liver disease) or previous transplant
were not included. All subjects underwent a complete neurological
and cardiological evaluation. The eligibility criteria were determined
by interviewing both participants and their relatives as well as by
reviewing participants’ medical records. In all, 10 patients were
excluded because of technical–methodological reasons (3 patients
obtained a kidney transplant before neuropsychological testing was
conducted, 2 did not return for follow-up, 4 received a kidney graft
shortly after their second assessment as being in the NTX group, and
1 lost his graft and returned on dialysis) and 4 subjects did not meet
the inclusion criteria (1 was on psychoactive medication, 1 had
severe hearing difficulties, and 2 had a history of kidney
transplantation). These 14 individuals were, however, similar to
our 45 dialyzed patients with regard to age, sex, education, as well as
specific CKD-related factors. Importantly, although we did not
specifically exclude individuals with asymptomatic carotid artery
stenosis, atrial fibrillation, or congestive heart failure, none of our
participants suffered from any of these conditions. During the study
period, none of the patients was converted from hemodialysis to
peritoneal dialysis or vice versa.
Out of the total of 45 dialyzed individuals awaiting kidney
transplantation, 27 patients received kidney graft within 214 days
(range 123–297 days) from baseline testing. Hence, they formed the
TX group and the remaining 18 patients formed the NTX group. It
is noteworthy that because of the unpredictable organ availability,
the time between baseline and transplantation was variable and
rather long. For subjects who underwent transplantation, the first
follow-up point wasB34 days (range 12–57 days) after the surgery.
In all but one case, the transplant was obtained from a deceased
donor. At the time of both follow-up evaluations, the renal function
in each graft recipient was adequate (see Table 2). Additionally,
during each testing session, all patients with kidney transplant were
stable and none of them presented with any postoperative
complications. In 14 patients a single episode of graft rejection
and/or infection was diagnosed within the first 5 months after
transplantation. These complications were successfully treated and
none of the patients required dialysis. As a form of immunosup-
pressive therapy, individuals with kidney graft received cyclosporine
or tacrolimus, mycophenolate mofetil or mycophenolate sodium,
and steroids. During the first follow-up, all of these patients received
steroids 415 mg (range 20–45). Nonetheless, none of them was on
doses 415 mg at the second follow-up. In cases when subsequently
to transplantation patients developed diabetes or hypertension,
they were additionally treated with antidiabetic or antihypertensive
agents.
Matched controls
All 30 matched controls, with no history of nephrological problems
(mean glomerular filtration rate¼ 116.2 ml/min per 1.73 m2;
s.d.¼ 10.7), were subject to the same eligibility criteria as patients
with ESRD. Importantly, they were recruited after the dialyzed
subjects were enrolled. Thus, having known the demographics and
the comorbidities of our dialyzed patients, 16 participants were
recruited from a group of 20 individuals from the Outpatient
Hypertension and Diabetology Clinic, Medical University of
Gdan˜sk, and 14 subjects were selected from a pool of 30 randomly
recruited citizens of Gdan´sk.
Procedure
All participants were tested in the same way and the neuropsycho-
logical measures were given in the same order. Additionally, each
subject was evaluated at the same time of the day (±3 h) and
patients on hemodialysis were tested B24 h after receiving the last
dialysis. All participants were examined in the same testing room
and blood samples for biochemical data were always obtained
shortly after completion of cognitive assessment; thus, the
venopuncture pain did not interfere with the neuropsychological
performance. Also, each subject underwent a complete neurological
and cardiac evaluation. None of participants was ill or hospitalized
during the assessment. All data included in this manuscript were
obtained in compliance with regulations of our institutions, and
before testing informed consent was acquired from each study
participant.
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Neuropsychological assessment
The cognitive performance of all participants was evaluated using a
battery of standardized neuropsychological measures.41,42,50–55 A detailed
description of each test, including the administration procedure, has
been previously published.2,37
Statistical analysis
A series of one-way analysis of variance (for continuous data)
and w2 tests (for categorical data) were performed using SPSS
version 18 (SPSS Polska Sp. Z.0.0., Krakco´w, PL) for Windows to
compare groups on demographics and selected clinical measures.
The clinical and biochemical factors specific only for groups with
ESRD were compared using Student’s t-tests for independent samples
or w2 tests.
Prospective comparisons of neuropsychological scores of all
groups were performed using (3 3) repeated measures analysis of
variance, with the within-subject factor being time of testing
(baseline vs first follow-up vs second follow-up), and the between-
subject factor being group (TX vs NTX vs matched controls). The
dependent variable was a mean raw score obtained in each
neuropsychological measure. The percentage of change in cognitive
performance was calculated using the following formula: ((raw
scorefollow-up–raw scorebaseline)/raw scorebaseline) 100%, and then
compared between groups. For the Trail Making Test, where scores
reflect time needed to complete the task, results of these calculations
were multiplied by 1, so that, similar to other tests, positive
numbers indicated improved performance, as shown in Table 3.
Importantly, for neuropsychological analysis, significance level
was corrected for multiple comparisons and was set at Pp0.002. The
post hoc comparisons of between-group effects were in all cases
conducted using Tukey’s test, whereas pairwise comparisons
with Bonferroni corrections were applied to test for the learning
effect in matched controls. The effect sizes in repeated measures
analysis of variance (Zp2) were computed using the procedure
implemented in SPSS.
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